Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8114967 | 0.92 | KDM4E (0.47) | CYP11B1CYP11B2TNFTLR7ADORA2A | |
| SCHEMBL28802666 | 0.89 | TNF (0.41) | CYP11B1CYP11B2TNFTLR7ADORA2A | |
| SCHEMBL10737860 | 0.87 | HTT (0.51) | CYP11B1CYP11B2TNFTLR7ADORA2A | |
| SCHEMBL29808930 | 0.86 | MAOB (0.48) | LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL24733009 | 0.86 | MAOB (0.48) | LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL10732746 | 0.85 | TLR7 (0.51) | CYP11B1CYP11B2TNFTLR7ADORA2A | |
| SCHEMBL8121523 | 0.85 | KDM4E (0.46) | TLR7ADORA2ALMNAPOLBHRH2 | |
| SCHEMBL29977334 | 0.84 | HTT (0.42) | CYP11B1CYP11B2TLR7ADORA2ALMNA | |
| SCHEMBL9199346 | 0.84 | CYP11B1 (0.53) | CYP11B1CYP11B2TNFTLR7ADORA2A | |
| SCHEMBL3188618 | 0.84 | TLR7 (0.67) | TLR7ADORA2ALMNAPOLBHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134701-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | THE UNIVERSITY OF KANSAS | 2018-05-17 | — | — | US | disclosed |
| US-20180134701-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | THE UNIVERSITY OF KANSAS | 2018-05-17 | — | — | US | disclosed |
| EP-0310950-B1 | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes | RIKER LABORATORIES, INC. (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0145340-B1 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0310950-A1 | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes | RIKER LABORATORIES, INC. (US) | 1989-04-12 | — | — | EP | disclosed |
| US-4698348-A | 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents | RIKER LABORATORIES, INC. (US) | 1987-10-06 | — | — | US | disclosed |
| US-4689338-A | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use | RIKER LABORATORIES, INC. (US) | 1987-08-25 | — | — | US | disclosed |
| EP-0145340-A2 | 1H-Imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134701-A1 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS | TLR7, TLR8, TLR3 | CYP11B1 4457/4885CYP11B2 3986/4885TNF 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.